Literature DB >> 12206280

Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research.

John B Murray1.   

Abstract

Phencyclidine (PCP) is a dangerous drug, and the federal government has placed it on Schedule II of the Controlled Substance Act (see http:// www .mninter.net/-publish/csa2.htm#Schedule%20III). Typically, users smoke PCP, and it is often mixed with parsley, marijuana, or cocaine. Most researchers have conducted experiments on animals rather than on people, and a few have been done on persons diagnosed with schizophrenia, so answers to questions about its addictive potential or development of tolerance are not clear. In healthy volunteers, PCP can induce symptoms that mimic those of schizophrenia, lasting from a few days to more than a week. The neurotransmitter glutamate and N-methyl-D-aspartate (NMDA) appear to play a role in the mechanism by which PCP induces positive and negative schizophrenic symptoms and cognitive defects (D. C. Javitt & S. R. Zukin, 1991; A. Lahti, B. Koffel, D. LaPorte, & C. A. Tamminga, 1995; T. W. Robbins, 1990). Because PCP can induce symptoms that are almost indistinguishable from those associated with schizophrenia, further research may lead to new medications that could be helpful to people who do not respond to neuroleptics that are currently available.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12206280     DOI: 10.1080/00223980209604159

Source DB:  PubMed          Journal:  J Psychol        ISSN: 0022-3980


  12 in total

1.  Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure.

Authors:  Samantha L Rushforth; Thomas Steckler; Mohammed Shoaib
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.

Authors:  Matcheri S Keshavan; Henry A Nasrallah; Rajiv Tandon
Journal:  Schizophr Res       Date:  2011-02-12       Impact factor: 4.939

Review 3.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

Authors:  Joanne Bowes; Andrew J Brown; Jacques Hamon; Wolfgang Jarolimek; Arun Sridhar; Gareth Waldron; Steven Whitebread
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

4.  N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice.

Authors:  David-Marian Otte; Britta Sommersberg; Alexei Kudin; Catalina Guerrero; Onder Albayram; Michaela D Filiou; Pamela Frisch; Oznur Yilmaz; Eva Drews; Christoph W Turck; Andras Bilkei-Gorzó; Wolfram S Kunz; Heinz Beck; Andreas Zimmer
Journal:  Neuropsychopharmacology       Date:  2011-06-29       Impact factor: 7.853

Review 5.  New insights on endocannabinoid transmission in psychomotor disorders.

Authors:  Andrea Giuffrida; Alexandre Seillier
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-10       Impact factor: 5.067

6.  Substance use and abuse in first-episode psychosis: prevalence before and after early intervention.

Authors:  Suzanne Archie; Brian R Rush; Noori Akhtar-Danesh; Ross Norman; Ashok Malla; Paul Roy; Robert B Zipursky
Journal:  Schizophr Bull       Date:  2007-03-03       Impact factor: 9.306

7.  Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.

Authors:  Ming Li; Wei He; Alexa Mead
Journal:  Behav Pharmacol       Date:  2009-02       Impact factor: 2.293

8.  The association between phencyclidine use and partner violence: an initial examination.

Authors:  Cory A Crane; Caroline J Easton; Susan Devine
Journal:  J Addict Dis       Date:  2013

Review 9.  The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention.

Authors:  Anthony A Grace; Felipe V Gomes
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

10.  Is the History of Substance Abuse Correlated with Neuropsychiatric Disorders and Co-morbid HIV Infection? An Urban Population Study.

Authors:  R B Bassey; S N Chapman; M Pessu; A Jayam-Trouth; M C Gondré-Lewis
Journal:  J Neurol Neurosci       Date:  2018-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.